Blackstone Life Sciences

Founded in 2005, Blackstone Life Sciences is a venture capital firm focused on the life sciences sector. It invests in biopharmaceuticals, specialty pharma, medical devices, and diagnostic spaces, with a preference for cancer drugs and treatments for inflammatory and urological disorders. The firm targets investments in companies based in the United States and Europe, typically ranging from $15 million to $100 million per company.

Paris Panayiotopoulos

Senior Managing Director and Investment Committee Member

Kiran Reddy MD

Senior Managing Director

Kurt Wheeler

Operating Partner

15 past transactions

AvenCell

Series B in 2024
Based on our deep science and focused on patients in need.

Uniquity Bio

Series A in 2024
Uniquity Bio is a clinical-stage drug development company dedicated to advancing innovative therapies, particularly in the fields of immunology and inflammation. The company is focused on identifying and developing novel therapeutics that aim to deliver transformative benefits to patients suffering from conditions with limited or no treatment options. Leveraging the expertise of seasoned pharmaceutical executives, Uniquity Bio effectively drives its research and development initiatives. With strong backing from notable investors, the company is well-positioned to fulfill its mission of delivering groundbreaking medicines to the healthcare market.

Moderna

Post in 2024
Moderna, Inc. is a biotechnology company established in 2010 and headquartered in Cambridge, Massachusetts. The company specializes in developing therapeutics and vaccines using messenger RNA (mRNA) technology, which provides instructions for cells to produce proteins essential for various biological functions. Moderna has a diverse pipeline, with numerous programs targeting infectious diseases, immuno-oncology, rare diseases, and cardiovascular conditions. As of September 2024, it has 40 mRNA development candidates in clinical trials across multiple therapeutic areas. The company's mRNA technology gained significant recognition with the authorization of its COVID-19 vaccine in December 2020. Moderna maintains strategic alliances with various organizations, including major pharmaceutical companies and research institutions, to enhance its research and development efforts.

Amicus Therapeutics

Post in 2023
Amicus Therapeutics is a biotechnology company focused on discovering, developing, and delivering therapies for rare and orphan diseases. It specializes in oral pharmacological chaperones—small molecules that bind, stabilize, and enhance activity of misfolded enzymes—to treat lysosomal storage disorders such as Fabry and Pompe disease, and it explores combination approaches with enzyme replacement therapy. The company maintains a growing pipeline targeting additional lysosomal diseases, including Gaucher, and collaborates with academic and clinical partners to advance its programs. Amicus was founded in 2002 and is headquartered in Cranbury, New Jersey.

Sutro Biopharma

Post in 2023
Sutro Biopharma is a clinical-stage biopharmaceutical company focused on developing next-generation protein therapeutics for cancer and autoimmune disorders using its proprietary XpressCF platform. Its pipeline includes STRO-001 for multiple myeloma and non-Hodgkin lymphoma, and STRO-002 for ovarian and endometrial cancers.

PTC Therapeutics

Post in 2022
PTC Therapeutics is a biopharmaceutical company dedicated to discovering, developing, and commercializing treatments for rare genetic disorders. Its portfolio includes approved drugs like Translarna (ataluren) and Emflaza (deflazacort), as well as pipeline candidates targeting various rare diseases such as Duchenne muscular dystrophy, spinal muscular atrophy, and certain cancers.

Sanofi

Post in 2022
Sanofi is a global pharmaceutical company headquartered in Paris that researches, develops, manufactures, and markets medicines and vaccines for a broad range of diseases. Its portfolio covers diabetes, oncology, immunology, cardiovascular diseases, and rare disorders, along with consumer healthcare products. Sanofi pursues innovation across biologics and small-molecule therapies and maintains a robust vaccine program to address infectious diseases. The company emphasizes patient-oriented research and collaborates with partners to bring new treatments to patients worldwide.

Harmony Biosciences Holdings

Post in 2021
Harmony Biosciences Holdings is a commercial-stage pharmaceutical company based in Plymouth Meeting, Pennsylvania, founded in 2017. It develops and commercializes therapies for rare neurological disorders with unmet medical needs. Its lead product is WAKIX (pitolisant), used to treat narcolepsy, and the company maintains a pipeline that includes candidates such as HBS-102, BP1.15205, ZYN002, EPX-100 and EPX-200.

Talaris Therapeutics

Series B in 2020
Talaris Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies aimed at eliminating chronic immunosuppression for organ transplant recipients. The company's leading product, FCR001, is designed to enable living donor kidney transplant recipients to discontinue all chronic immunosuppression therapy within twelve months post-transplant. In addition to its applications in organ transplantation, Talaris’s technology facilitates the safe use of hematopoietic stem cells from unmatched and unrelated donors for bone marrow transplants, reducing the associated toxicity and risks of traditional methods. Founded in 1988 and originally named Regenerex, Inc., Talaris Therapeutics rebranded in March 2019. The company is headquartered in Louisville, Kentucky, with an additional office in Wellesley, Massachusetts.

Annexon Biosciences

Series D in 2020
Annexon Biosciences is a clinical-stage biopharmaceutical company focused on developing novel therapies for patients with classical complement-mediated disorders affecting the body, brain, and eye. The company's pipeline is built on a platform technology that targets well-researched autoimmune and neurodegenerative disease processes triggered by the aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon's lead product candidate, ANX005, is a full-length monoclonal antibody designed for intravenous administration to treat autoimmune and neurodegenerative disorders. Another key candidate, ANX007, is a monoclonal antibody Fab formulated for intravitreal administration to address neurodegenerative ophthalmic disorders. The company employs a biomarker-driven development strategy to ensure that its product candidates effectively engage the target at therapeutic doses within the intended patient tissue, while also exploring additional orphan and large market indications.

Medtronic

Post in 2020
Medtronic specializes in healthcare technology solutions, addressing complex conditions across various medical fields such as cardiac devices, insulin pumps, patient monitoring systems, and robotic surgery. The company's innovative technologies treat over 70 different medical conditions globally.

Reata Pharmaceuticals

Post in 2020
Reata Pharmaceuticals is a biopharmaceutical company focused on developing novel therapeutics for patients with serious or life-threatening diseases. It targets molecular pathways that regulate cellular metabolism and inflammation, with a primary focus on renal, cardiovascular, and autoimmune indications.

Alnylam Pharmaceuticals

Post in 2020
Alnylam Pharmaceuticals is a biopharmaceutical company specializing in the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company focuses on addressing rare genetic diseases, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system/ocular disorders. Its marketed products include ONPATTRO, a treatment for hereditary transthyretin-mediated amyloidosis, and GIVLAARI, which targets acute hepatic porphyria. Alnylam’s pipeline includes investigational therapies such as givosiran for acute hepatic porphyria, lumasiran for primary hyperoxaluria type 1, and vutrisiran for transthyretin amyloidosis. The company has established strategic alliances with notable partners like Sanofi Genzyme and Regeneron Pharmaceuticals, and it collaborates with Vir Biotechnology on RNAi therapeutics for coronavirus infections. Founded in 2002 and headquartered in Cambridge, Massachusetts, Alnylam Pharmaceuticals is at the forefront of transforming RNAi science into innovative medicines to improve patient outcomes.

Anthos Therapeutics

Series A in 2019
Anthos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on advancing therapies for cardiovascular and metabolic diseases. Founded in 2018, the company specializes in developing innovative treatments that target Factor XI and XIa, critical components of the intrinsic coagulation pathway. Its lead product, MAA868, is an anti-thrombotic investigational therapy designed to prevent thrombotic events while minimizing the risk of bleeding. By offering a long-acting treatment paradigm, Anthos Therapeutics aims to provide significant advantages over conventional standards of care, ultimately enhancing patient outcomes in cardiovascular health.

GRIN Therapeutics

GRIN Therapeutics is a clinical-stage biotechnology company focused on developing precision therapeutics for serious pediatric neurodevelopmental disorders. It targets conditions arising from GRIN gene mutations and related neurodevelopmental disorders and is advancing the investigational therapy radiprodil to evaluate its safety and efficacy for GRIN-related disorders, tuberous sclerosis complex, and focal cortical dysplasia.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.